Finally, modulating MCAD activity in TAMs through treatment with caspase-1 inhibitors or genetic manipulation suppressed primary tumor growth in in vivo mouse models, thus supporting potential clinical applications for targeting the caspase-1/PPARγ/MCAD pathway in TAM differentiation. This evidence concerns the gene CASP1 and neoplasm.